Inhibition of Dengue NS2B-NS3 Protease and Viral Replication in Vero Cells by Recombinant Retrocyclin-1

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2012 Nov 23

PMID 23171075

Citations 37

Authors

Hussin A Rothan

Heh Choon Han

Thamil Selvee Ramasamy

Shatrah Othman

Noorsaadah Abd Rahman

Rohana Yusof

Affiliations

Soon will be listed here.

Abstract

Background: Global resurgence of dengue virus infections in many of the tropical and subtropical countries is a major concern. Therefore, there is an urgent need for the development of successful drugs that are both economical and offer a long-lasting protection. The viral NS2B-NS3 serine protease (NS2B-NS3pro) is a promising target for the development of drug-like inhibitors, which are not available at the moment. In this study, we report retrocyclin-1 (RC-1) production in E. coli as a recombinant peptide to test against dengue NS2B-NS3pro.

Methods: Dengue NS2B-NS3pro was produced as a recombinant single chain protein in E. coli and purified by Ni+ affinity chromatography. The RC-1 peptide was produced in E. coli and the tri-disulphide bonds were reformed in a diluted alkaline environment. Protease assay was performed using a fluorogenic peptide substrate and measured by fluorescence spectrometry. Real-time PCR was used for quantification of dengue serotype 2 (DENV-2) viral RNA produced in Vero cells.

Results: The RC-1 peptide inhibited the activity of recombinant NS2B-NS3pro with different values at 50% inhibitory concentration (IC50) which are temperature dependent (28°C, 46.1 ± 1.7 μM; 37°C, 21.4 ± 1.6 μM; 40°C, 14.1 ± 1.2 μM). The presence of RC-1 significantly reduced viral replication in Vero cells infected with DENV-2 at simultaneous treatment after 48 hrs (70%) and 75 hrs (85%). Furthermore, moderate reduction in viral replication was observed at pre-treatment mode after 48 hrs (40%) and 72 hrs (38%) and post-treatment at 48 hrs (30%) and 72 hrs (45%).

Conclusion: Recombinant RC-1 inhibits DENV-2 replication in Vero cells by interfering with the activity of its serine protease. Thus, we propose that recombinant RC-1 is a potent, cost-effective dengue virus inhibitor. Therefore, it is suitable to consider RC-1 as a new candidate for drug development against dengue infection.

Citing Articles

Evaluation of methoxyflavones as dengue NS2B-NS3 protease inhibitors: an in silico and in vitro studies.

Mustafa N, Cheng K, Razali S, Wahab H, Salin N, Zakaria I Mol Divers. 2025; 29(2):1175-1187.

PMID: 39841317 DOI: 10.1007/s11030-024-10899-5.

Harnessing Natural Resources for Advancements in Dengue Virus Treatment.

Hapis N, Nor Rashid N, Choo Y Curr Top Med Chem. 2024; 24(27):2337-2350.

PMID: 39253916 DOI: 10.2174/0115680266312717240821062535.

Using Multiscale Molecular Modeling to Analyze Possible NS2b-NS3 Protease Inhibitors from Philippine Medicinal Plants.

Cordero A, Gonzales 3rd A Curr Issues Mol Biol. 2024; 46(7):7592-7618.

PMID: 39057092 PMC: 11275823. DOI: 10.3390/cimb46070451.

Dengue virus: pathogenesis and potential for small molecule inhibitors.

Chauhan N, Gaur K, Asuru T, Guchhait P Biosci Rep. 2024; 44(8).

PMID: 39051974 PMC: 11327219. DOI: 10.1042/BSR20240134.

Dengue virus pathogenesis and host molecular machineries.

Sinha S, Singh K, Ravi Kumar Y, Roy R, Phadnis S, Meena V J Biomed Sci. 2024; 31(1):43.

PMID: 38649998 PMC: 11036733. DOI: 10.1186/s12929-024-01030-9.

References

Geiss B, Stahla H, Hannah A, Gari A, Keenan S . Focus on flaviviruses: current and future drug targets. Future Med Chem. 2010; 1(2):327-44. PMC: 2822355. DOI: 10.4155/fmc.09.27. View

Wang W, Mulakala C, Ward S, Jung G, Luong H, Pham D . Retrocyclins kill bacilli and germinating spores of Bacillus anthracis and inactivate anthrax lethal toxin. J Biol Chem. 2006; 281(43):32755-64. PMC: 2440672. DOI: 10.1074/jbc.M603614200. View

Cole A, Cole A . Antimicrobial polypeptides are key anti-HIV-1 effector molecules of cervicovaginal host defense. Am J Reprod Immunol. 2007; 59(1):27-34. DOI: 10.1111/j.1600-0897.2007.00561.x. View

Murrell S, Wu S, Butler M . Review of dengue virus and the development of a vaccine. Biotechnol Adv. 2010; 29(2):239-47. DOI: 10.1016/j.biotechadv.2010.11.008. View

Stadler K, Allison S, Schalich J, Heinz F . Proteolytic activation of tick-borne encephalitis virus by furin. J Virol. 1997; 71(11):8475-81. PMC: 192310. DOI: 10.1128/JVI.71.11.8475-8481.1997. View

Arias C, Preugschat F, Strauss J . Dengue 2 virus NS2B and NS3 form a stable complex that can cleave NS3 within the helicase domain. Virology. 1993; 193(2):888-99. DOI: 10.1006/viro.1993.1198. View

Lobigs M . Flavivirus premembrane protein cleavage and spike heterodimer secretion require the function of the viral proteinase NS3. Proc Natl Acad Sci U S A. 1993; 90(13):6218-22. PMC: 46899. DOI: 10.1073/pnas.90.13.6218. View

Stocks C, Lobigs M . Signal peptidase cleavage at the flavivirus C-prM junction: dependence on the viral NS2B-3 protease for efficient processing requires determinants in C, the signal peptide, and prM. J Virol. 1998; 72(3):2141-9. PMC: 109509. DOI: 10.1128/JVI.72.3.2141-2149.1998. View

Rothan H, Abdulrahman A, Sasikumer P, Othman S, Rahman N, Yusof R . Protegrin-1 inhibits dengue NS2B-NS3 serine protease and viral replication in MK2 cells. J Biomed Biotechnol. 2012; 2012:251482. PMC: 3470887. DOI: 10.1155/2012/251482. View

10.

Chambers T, Hahn C, Galler R, Rice C . Flavivirus genome organization, expression, and replication. Annu Rev Microbiol. 1990; 44:649-88. DOI: 10.1146/annurev.mi.44.100190.003245. View

11.

Falgout B, Pethel M, Zhang Y, Lai C . Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins. J Virol. 1991; 65(5):2467-75. PMC: 240601. DOI: 10.1128/JVI.65.5.2467-2475.1991. View

12.

Tomlinson S, Malmstrom R, Watowich S . New approaches to structure-based discovery of dengue protease inhibitors. Infect Disord Drug Targets. 2009; 9(3):327-43. DOI: 10.2174/1871526510909030327. View

13.

Sijwali P, Brinen L, Rosenthal P . Systematic optimization of expression and refolding of the Plasmodium falciparum cysteine protease falcipain-2. Protein Expr Purif. 2001; 22(1):128-34. DOI: 10.1006/prep.2001.1416. View

14.

Cheng Y, Prusoff W . Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973; 22(23):3099-108. DOI: 10.1016/0006-2952(73)90196-2. View

15.

Liang Q, Zhou K, He H . Retrocyclin 2: a new therapy against avian influenza H5N1 virus in vivo and vitro. Biotechnol Lett. 2009; 32(3):387-92. DOI: 10.1007/s10529-009-0167-2. View

16.

Tambunan U, Alamudi S . Designing cyclic peptide inhibitor of dengue virus NS3-NS2B protease by using molecular docking approach. Bioinformation. 2011; 5(6):250-4. PMC: 3055701. DOI: 10.6026/97320630005250. View

17.

Penberthy W, Chari S, Cole A, Cole A . Retrocyclins and their activity against HIV-1. Cell Mol Life Sci. 2011; 68(13):2231-42. PMC: 4511374. DOI: 10.1007/s00018-011-0715-5. View

18.

Owen S, Rudolph D, Wang W, Cole A, Waring A, Lal R . RC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates. AIDS Res Hum Retroviruses. 2004; 20(11):1157-65. DOI: 10.1089/aid.2004.20.1157. View

19.

Steuer C, Heinonen K, Kattner L, Klein C . Optimization of assay conditions for dengue virus protease: effect of various polyols and nonionic detergents. J Biomol Screen. 2009; 14(9):1102-8. DOI: 10.1177/1087057109344115. View

20.

Lin C, Amberg S, Chambers T, Rice C . Cleavage at a novel site in the NS4A region by the yellow fever virus NS2B-3 proteinase is a prerequisite for processing at the downstream 4A/4B signalase site. J Virol. 1993; 67(4):2327-35. PMC: 240389. DOI: 10.1128/JVI.67.4.2327-2335.1993. View